🇺🇸 FDA
Patent

US 9676840

Anti-CD100 neutralizing antibodies and methods of using the same

granted A61KA61K2039/505A61K38/1774

Quick answer

US patent 9676840 (Anti-CD100 neutralizing antibodies and methods of using the same) held by VACCINEX, INC. expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/505, A61K38/1774, A61K39/0001, A61K39/3955